5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme

Inclusion Criteria

• •Patients must be at least 18 years of age.
• •Patients must have confirmed glioblastoma multiforme (GBM)
• •Maximum postoperative dimension of cavity plus residual contrast enhancing tumor of \< \* If a patient is found on the radiation planning scan to have a tumor target larger than this size, the patient will be removed from the study.
• •Patient must be selected for standard temozolomide chemotherapy to be administered with radiotherapy.
• •Patient agrees to have 10 week follow-up visit at a participating Johns Hopkins facility.
• •Patient agrees to allow access to or provide clinical, imaging, and laboratory follow-up information for three years whether or not obtained from Johns Hopkins providers.
• •3.1.7. Patients must not have received prior radiation therapy, chemotherapy, immunotherapy or therapy with biologic agents (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, Tumor-infiltrating lymphocytes (TIL), Lymphokine-Activated Killer Cell (LAK) or gene therapy), or hormonal therapy for their brain tumor. Glucocorticoid therapy is allowed.
• •Patients must have a Karnofsky performance status 60% or higher (i.e. the patient must be able to care for himself/herself with occasional help from others).
• •Patients must be able to provide written informed consent.
• •Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Women of childbearing potential must have a negative pregnancy test.
• •Patients must be able to undergo MRI scan with gadolinium contrast for treatment planning.